Antiangiogenic agents in head and neck squamous cell carcinoma: Tired of going solo

Antiangiogenic therapies as single agents have failed to demonstrate significant antitumor activity in heavily pretreated, unselected populations with recurrent/metastatic head and neck squamous cell carcinoma. Much work is needed to evaluate rational strategies for combining antiangiogenic agents with other systemic therapies or with radiotherapy for head and neck squamous cell carcinoma to move the field forward. See also pages 000-000.

from Cancer via ola Kala on Inoreader http://ift.tt/2cAVzqI
via IFTTT